FAP and adenoma: For activation of CTNNB1, 33 (56%) of 59 adenoma samples were CTNNB1-activation(+) whereas seven (70%) of 10 cancer samples were CTNNB1-activation(+) in low-methylation FAP samples, showing frequent activation in both adenoma and cancer with no significant difference (P = 0.5) (Figure 5C).